This review examines the mechanisms of cardiotoxicity from various cancer therapies and proposes areas for prevention, highlighting the role of induced pluripotent stem cell cardiomyocytes and genetics.
This review summarizes the mechanisms of cardiotoxicity associated with various cancer therapies and explores prevention strategies and future research directions in cardio-oncology.
Cardiotoxicity is a well-recognized late effect among childhood cancer survivors. With various pediatric cancers becoming increasingly curable, it is imperative to understand the disease burdens that survivors may face in the future. In order to prevent or mitigate cardiovascular complications, we must first understand the mechanistic underpinnings. This review will examine the underlying mechanisms of cardiotoxicity that arise from traditional antineoplastic chemotherapies, radiation therapy, hematopoietic stem cell transplantation, as well as newer cellular therapies and targeted cancer therapies. We will then propose areas for prevention, primarily drawing from the anthracycline-induced cardiotoxicity literature. Finally, we will explore the role of human induced pluripotent stem cell cardiomyocytes and genetics in advancing the field of cardio-oncology.
Fraley et al. (Tue,) conducted a review in Cardiotoxicity in childhood cancer survivors. Cancer therapy was evaluated. This review examines the mechanisms of cardiotoxicity from various cancer therapies and proposes areas for prevention, highlighting the role of induced pluripotent stem cell cardiomyocytes and genetics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: